EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.
A. M. Eggermont
Consultant or Advisory Role - Schering-Plough
Honoraria - Schering-Plough
Research Funding - Schering-Plough
Expert Testimony - Schering-Plough
S. Suciu
No relevant relationships to disclose
M. Santinami
No relevant relationships to disclose
W. Kruit
No relevant relationships to disclose
A. Testori
Consultant or Advisory Role - Schering-Plough
J. Marsden
No relevant relationships to disclose
C. J. A. Punt
No relevant relationships to disclose
M. E. Gore
No relevant relationships to disclose
R. MacKie
No relevant relationships to disclose
R. Dummer
Consultant or Advisory Role - Schering-Plough
D. Schadendorf
Consultant or Advisory Role - Schering-Plough
P. Patel
Consultant or Advisory Role - Schering-Plough
A. Spatz
No relevant relationships to disclose
U. Keilholz
Consultant or Advisory Role - Schering-Plough